Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent, No Country

Print

Management of type 2 diabetes requires the maintenance of good glycaemic control together with tight control of blood lipid levels and blood pressure.
 
Next»

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development